Viking Therapeutics Inc VKTX

NAS: VKTX | ISIN: US92686J1060   3/05/2024
76,97 USD (+1,60%)
(+1,60%)   3/05/2024

24 april 2024 · Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

17 april 2024 · Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 · Persbericht

26 maart 2024 · Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 · Persbericht

4 maart 2024 · Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

29 februari 2024 · Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock · Persbericht

27 februari 2024 · Viking Therapeutics Announces Proposed Public Offering of Common Stock · Persbericht

27 februari 2024 · Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity · Persbericht

7 februari 2024 · Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update · Persbericht

31 januari 2024 · Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024 · Persbericht

2 november 2023 · Viking Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

25 oktober 2023 · Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

23 oktober 2023 · Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity · Persbericht

18 oktober 2023 · Viking Therapeutics to Report Financial Results for Third Quarter 2023 on October 25, 2023 · Persbericht

18 oktober 2023 · Thinking about buying stock in Tempest Therapeutics, VinFast Auto, AGNC Investment, Ardelyx, or Viking Therapeutics? · Persbericht

17 oktober 2023 · Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 · Persbericht

10 oktober 2023 · Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 · Persbericht

7 september 2023 · Viking Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

6 september 2023 · Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity · Persbericht

26 juli 2023 · Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

19 juli 2023 · Viking Therapeutics to Report Financial Results for Second Quarter 2023 on July 26, 2023 · Persbericht

Mijn selecties